Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov;20(3):e25024.
doi: 10.1002/jia2.25024.

Gp41 and Gag amino acids linked to HIV-1 protease inhibitor-based second-line failure in HIV-1 subtype A from Western Kenya

Mia Coetzer  1 , Lauren Ledingham  1 , Lameck Diero  2   3 , Emmanuel Kemboi  2 , Millicent Orido  2 , Rami Kantor  1
Affiliations

Gp41 and Gag amino acids linked to HIV-1 protease inhibitor-based second-line failure in HIV-1 subtype A from Western Kenya

Mia Coetzer et al. J Int AIDS Soc. 2017 Nov.

Abstract

Introduction: Failure of protease-inhibitor (PI)-based second-line antiretroviral therapy (ART) with medication adherence but no protease drug resistance mutations (DRMs) is not well understood. This study investigated the involvement of gp41 and gag as alternative mechanisms, not captured by conventional resistance testing and particularly relevant in resource-limited settings where third-line ART is limited.

Methods: We evaluated gp41 and gag for unique amino acids in seven subtype A infected Kenyans failing second-line therapy with no PI resistance yet detectable lopinavir (query dataset), compared to seven similar-setting patients with PI resistance or undetectable lopinavir and 69 publically available subtype A Kenyan whole-genomes sequences.

Results: Three gp41 (607T, 641L, 721I) and four gag (124S, 143V, 339P, 357S) amino acids were significantly more frequent in the query dataset compared to the other datasets, with significantly high co-occurrence.

Conclusion: The genotypic analysis of a unique group of HIV-1 subtype A infected patients, identified seven amino acids that could potentially contribute to a multi-gene mechanism of PI-based ART failure in the absence of PI DR mutations.

Keywords: HIV-1; Kenya; drug resistance; gag; gp41; protease; subtype A.

PubMed Disclaimer

References

    1. Ajose O, Mookerjee S, Mills EJ, Boulle A, Ford N. Treatment outcomes of patients on second‐line antiretroviral therapy in resource‐limited settings: a systematic review and meta‐analysis. AIDS. 2012;26(8):929–38. - PubMed
    1. Ali A, Bandaranayake RM, Cai Y, King NM, Kolli M, Mittal S, et al. Molecular basis for drug resistance in HIV‐1 protease. Viruses. 2010;2(11):2509–35. - PMC - PubMed
    1. Lee SK, Potempa M, Swanstrom R. The choreography of HIV‐1 proteolytic processing and virion assembly. J Biol Chem. 2012;287(49):40867–74. - PMC - PubMed
    1. Hosseinipour MC, Gupta RK, Van Zyl G, Eron JJ, Nachega JB. Emergence of HIV drug resistance during first‐ and second‐line antiretroviral therapy in resource‐limited settings. J Infect Dis. 2013;207(Suppl 2):S49–56. - PMC - PubMed
    1. Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, Wilson CC, et al. Efficacy of a nucleoside‐sparing regimen of darunavir/ritonavir plus raltegravir in treatment‐naive HIV‐1‐infected patients (ACTG A5262). AIDS. 2011;25(17):2113–22. - PMC - PubMed

MeSH terms

Substances

Associated data